<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04492020</url>
  </required_header>
  <id_info>
    <org_study_id>3110-304-002</org_study_id>
    <nct_id>NCT04492020</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants</brief_title>
  <acronym>UBR Prodrome</acronym>
  <official_title>Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute&#xD;
      Treatment of Migraine When Administered During the Prodrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2020</start_date>
  <completion_date type="Anticipated">July 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants reporting absence of headache of moderate/severe intensity within 24 hours post-dose</measure>
    <time_frame>24 hours after taking double-blind study intervention during the prodrome</time_frame>
    <description>The absence of a headache of moderate/severe intensity will be recorded by the participant in an eDiary within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting absence of headache of any intensity within 24 hours post-dose</measure>
    <time_frame>24 hours after taking double-blind study intervention during the prodrome</time_frame>
    <description>The absence of a headache of any intensity will be recorded by the participant in an eDiary within 24 hours after taking double-blind study intervention during the prodrome in order to determine the prevention of the headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting absence of headache of moderate or severe intensity within 48 hours post-dose</measure>
    <time_frame>48 hours after taking doubleblind study intervention during the prodrome</time_frame>
    <description>The absence of a headache of moderate or severe intensity will be recorded by the participant in an eDiary within 48 hours after taking doubleblind study intervention during the prodrome in order to determine the prevention of headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting improvement in the ability to function normally within 24 hours post-dose</measure>
    <time_frame>24 hours after taking double-blind study intervention during the prodrome</time_frame>
    <description>The Functional Disability Scale (FDS) is a single item used to measure the participant's level to function normally. Participants will be asked to rate the performance of daily activities using 4 response options ranging from 0 (no disability, able to function normally) to 3 (severely impaired, cannot do all or most things, bed rest may be necessary) within 24 hours after taking double-blind study intervention during the prodrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ubrogepant 100mg</intervention_name>
    <description>For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least a 1-year history of migraine with or without aura consistent with a diagnosis&#xD;
             according to the ICHD-3 (International Classification of Headache Disorders 3rd&#xD;
             edition)&#xD;
&#xD;
          -  Migraine onset before age 50 years&#xD;
&#xD;
          -  By history, the participant's migraines typically last between 4 and 72 hours if&#xD;
             untreated or treated unsuccessfully and migraine episodes are separated by at least 48&#xD;
             hours of headache pain freedom.&#xD;
&#xD;
          -  History of 2 to 8 migraine attacks per month with moderate to severe headache in each&#xD;
             of the 3 months prior to the Screening Visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Difficulty distinguishing migraine headache from tension-type or other headaches&#xD;
&#xD;
          -  Participants who overuse medication for migraine defined as use of opioids or&#xD;
             barbiturates &gt; 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics&#xD;
             (eg, aspirin, NSAIDs, acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1&#xD;
             per investigator's judgment&#xD;
&#xD;
          -  Has a history of migraine aura with diplopia or impairment of level of consciousness,&#xD;
             hemiplegic migraine, or retinal migraine as defined by ICHD-3&#xD;
&#xD;
          -  A current diagnosis of chronic migraine as defined by ICHD-3 or a history of 15 or&#xD;
             more headache days per month on average in the 6 months prior to Visit 1 in the&#xD;
             investigator's judgment. A headache day is defined as a day in which there was any&#xD;
             occurrence of a headache of a minimum duration of 2 hours or a headache of any&#xD;
             duration for which acute medication was taken.&#xD;
&#xD;
          -  Has a current diagnosis of new persistent daily headache, trigeminal autonomic&#xD;
             cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3&#xD;
&#xD;
          -  Required hospital treatment of a migraine attack 3 or more times in the 6 months prior&#xD;
             to Visit 1.&#xD;
&#xD;
          -  History of malignancy in the 5 years prior to Visit 1, except for adequately treated&#xD;
             basal cell or squamous cell skin cancer, or in situ cervical cancer&#xD;
&#xD;
          -  History of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory&#xD;
             bowel disease) that, per investigator judgment, may affect the absorption or&#xD;
             metabolism of the study intervention; participants with prior gastric bariatric&#xD;
             interventions (eg, Lap Band) which have been reversed are not excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC /ID# 237098</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barrow Neuro Institute /ID# 236775</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Clinical Research /ID# 238032</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Headache and Balance Center /ID# 236247</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Valley Research Center /ID# 236561</name>
      <address>
        <city>Imperial</city>
        <state>California</state>
        <zip>92251-9401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wr-Pri Llc /Id# 236007</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute (PRI) - Newport Beach (Wake) /ID# 237691</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Excell Research, Inc /ID# 237721</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>George J. Rederich M.D. Inc. /ID# 235769</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research /ID# 237570</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Springs Neurological Associates (CSNA) /ID# 236556</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907-5302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Research, LLC /ID# 237426</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare - Jacksonville /ID# 238245</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256-6039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc - Jupiter /ID# 236226</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458-7021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research /ID# 236934</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare /ID# 238090</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc /ID# 236608</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801-2986</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites - St Petersburg Clinical Research Unit /ID# 237163</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709-3113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida /ID# 234387</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research /ID# 237092</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute - Palm Beach /ID# 238193</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407-3209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research Inc. /ID# 237365</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC /ID# 237390</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research - Neurology - Savannah /ID# 234371</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406-2758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta - Headlands LLC /ID# 234438</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281-9054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials Inc. /ID# 234968</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic Downtown /ID# 236959</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713-1227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of McFarland /ID# 238271</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010-5733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas Institute of Research /ID# 236738</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211-1363</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Collective Medical Research /ID# 236402</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials /ID# 236559</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131-2515</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Headache &amp; Neurological Institute (MHNI) /ID# 236565</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104-5131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology - Golden Valley /ID# 238162</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422-4215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc /ID# 238301</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402-2606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research /ID# 236457</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinvest Research LLC /ID# 237908</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810-2607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princeton Center for Clinical Research /ID# 235734</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bio Behavioral Health, Inc /ID# 238212</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755-6434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dent Neurosciences Research Center, Inc. /ID# 237039</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central New York Clinical Research /ID# 235694</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research /ID# 236842</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates /ID# 238220</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221-6046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte /ID# 237048</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates /ID# 237138</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center /ID# 237278</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 234403</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Columbus /ID# 236837</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OK Clinical Research /ID# 236675</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034-3257</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPS Research Company /ID# 237674</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Headlands LLC /ID# 236077</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates - Abington /ID# 236257</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lehigh Center for Clinical Research /ID# 236703</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104-5034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suburban Research Associates - Media /ID# 236698</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063-1760</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Jefferson Headache Center /ID# 235821</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research /ID# 237924</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of SC /ID# 237338</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>WR-ClinSearch /ID# 238287</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421-1605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare - Memphis /ID# 236396</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology /ID# 236428</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc. /ID# 237306</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DiscoveResearch, Inc /ID# 236273</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP /ID# 236276</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - Houston /ID# 237458</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinPoint Trials /ID# 236618</name>
      <address>
        <city>Waxahachie</city>
        <state>Texas</state>
        <zip>75165-1430</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute /ID# 237749</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah /ID# 237602</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research /ID# 237792</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc. (HRHR) /ID# 237253</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tidewater Integr Med Research /ID# 236867</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sentara Neurology Specialists - Virginia Beach /ID# 234350</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456-0019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center /ID# 237585</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Clinical Research Center /ID# 236912</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Puget Sound Neurology /ID# 236322</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>25328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.allerganclinicaltrials.com/,http://www.investigatordatabank.org/</url>
    <description>Additional information on study locations near you may be found at www.AllerganClinicalTrials.com.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

